Renal Toxicity After Radionuclide Therapy
Journal Title: Nuclear Medicine Seminars - Year 2019, Vol 5, Issue 3
Abstract
With the introduction of radionuclide therapies, the probability of toxicity has increased in critical organs such as kidney and bone marrow. Although these toxicity rates are relatively low in targeted therapies such as radionuclide therapy, a number of organs, especially the kidneys, are affected by radiation. Radionuclide therapies that led to the major risk for renal toxicity are neuroendocrine tumor treatment with beta-emitting radioisotopes (Lu-177 and Y-90) labeled with [DOTA0, Tyr3]-octreotate (DOTATATE), and prostate cancer treatment with alpha or beta emitters, such as Lu-177 or Ac-225, labeled with prostate specific membrane antigen. The intense uptake and prolonged retention of these radioactive molecules in the kidneys raise concerns about the potential toxicity of kidneys by radiation that puts therapeutic efficacy at risk. In this review, nephrotoxicity resulting from radionuclide therapy, particularly Lu-177 and Y-90, and therapeutic options to reduce the toxicity are discussed.
Authors and Affiliations
Nalan Alan Selçuk, Türkay Toklu
Keywords
Related Articles
- EP ID EP685341
- DOI 10.4274/nts.galenos.2019.0029
- Views 184
- Downloads 0
Acceptance and Quality Control Tests for the Single Photon Emission Computerized Tomography (SPECT) Gamma Cameras and SPECT/CT Systems
Scintigraphic images play an important role in the diagnosis of diseases by providing accurate clinical information independent of the operator. However, the good quality image may not be obtained due to changes in the p...
Options and Auxiliary Surgical Techniques in Residual or Recurrent Nodal Disease in Differentiated Thyroid Cancers
Despite their very good prognosis, residual or recurrent nodal disease can be seen in approximately 30% of patients in differentiated thyroid cancers (DTC). Nodal disease is most common in the neck and it can be treated...
Non-ultrasonographic and Non-radioiodine Imaging Techniques in Thyroid Cancer
Ultrasonography is the most commonly used and most effective imaging modality in thyroid cancer imaging. It is the most successful method for evaluating primary tumor and local disease. I-131 scintigraphy is also a usefu...
The Use of F-18-FDG PET/CT in Renal and Bladder Tumors
Clinical imaging has been the cornerstone to guide patient management and therapy strategies for oncology patients. In the last decades, the use of fluorodeoxyglucose positron emission tomography/computed tomography (PET...
F-18 FDG PET/CT Practice Guideline in Oncology
Positron emission tomography (PET) is a tomographic imaging method that shows three-dimensional distribution of radiopharmaceuticals which are labelled with positron emitter radionuclides. Today most widely used PET radi...